MOTS-c

Also known as: Mitochondrial-derived peptide

Evidence Tier Chigh riskadvancednot approved

Mitochondrial-derived peptide studied in mouse models for metabolic homeostasis and insulin sensitivity.

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

Not Approved

This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.

No Human Data

No human exposure data has been identified for this substance. All available evidence comes from animal models or in vitro studies. Safety in humans is completely unknown.

Overview

MOTS-c regulates metabolic homeostasis and improves insulin sensitivity in mouse models. Described as an exercise-induced mitochondrial-encoded peptide. Mouse studies use 0.5 mg/kg/day IP dosing. FDA states it has not identified human exposure data for MOTS-c compounded drug products and flags significant immunogenicity/characterization risks.

Research Details

Mechanism of Action

Regulates metabolic homeostasis; improves insulin sensitivity and reduces obesity/insulin resistance in mouse models.

Study Dose Range

Mouse: 0.5 mg/kg/day intraperitoneal. No established human dosing.

Administration Routes

subcutaneous

Onset / Timeline

Metabolic endpoints assessed over days to weeks in mice; exercise performance improvements after ~10 days.

Expected Effects

Preclinical: improved insulin sensitivity, metabolic regulation, exercise performance in mice.

Adverse Effects

FDA: no identified human exposure data; significant immunogenicity/characterization risks.

Contraindications

No human data.

Interaction Notes

Unknown.

Related Goals

Fat Loss & MetabolismLongevity & Anti-Aging

Available From

Amino Club

consumer RUO · COA: product page COA viewer

10 mg / 20 mg (variant-dependent) · variant-dependent on product page

Consumer RUO; review product details carefully

A dedicated MOTS-c page is available, which makes the listing easier to review directly.

USVisit Vendor

QC: third-party purity testing; product-level COA on page

Shipping: US/ROW (verify current policy) · affiliate: public program

Read this before you compare products

Peptide Lab Testing Explained

A practical breakdown of the testing methods people see on product pages and what those methods can and cannot prove.

Read guide

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Tesamorelin

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Tier A

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.